U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07178795) titled 'A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC' on Sept. 11.
Brief Summary: This trial is a registrational phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-M07D1 in patients with first-line treatment of HER2-mutant advanced or metastatic non-squamous non-small cell lung cancer.
Study Start Date: Sept., 2025
Study Type: INTERVENTIONAL
Condition:
Non-squamous Non-small Cell Lung Cancer
Intervention:
DRUG: BL-M07D1
Administration by intravenous infusion for a cycle of 3 weeks.
DRUG: Pembrol...